225 MET ECD shedding and use of targeted therapies 19. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61. 20. Szturz P, Budikova M, Vermorken JB, Horova I, Gal B, Raymond E, et al. Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data. Oral Oncol 2017;74:68-76. 21. Kim KH, Kim H. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy. Exp Mol Med 2017;49:e307. 22. Huang F, Ma Z, Pollan S, Yuan X, Swartwood S, Gertych A, et al. Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET. J Pathol Clin Res 2016;2:210-22. 23. Administration of USFD. Companion diagnostics. https://www.fda.gov/medical-devices/in-vitro-diagnostics/ companion-diagnostics. 2018. Accessed: 14.01.2022 2022. 24. Lefebvre J, Ancot F, Leroy C, Muharram G, Lemiere A, Tulasne D. Met degradation: more than one stone to shoot a receptor down. FASEB J 2012;26:1387-99. 25. Prat M, Crepaldi T, Gandino L, Giordano S, Longati P, Comoglio P. C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol 1991;11:5954-62. 26. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33. 27. Dean M, Park M, Le Beau MM, Robins TS, Diaz MO, Rowley JD, et al. The human met oncogene is related to the tyrosine kinase oncogenes. Nature 1985;318:385-8. 28. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A 1987;84:6379-83. 29. Giordano S, Di Renzo MF, Narsimhan RP, Cooper CS, Rosa C, Comoglio PM. Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene 1989;4:1383-8. 30. Giordano S, Di Renzo MF, Ferracini R, Chiado-Piat L, Comoglio PM. p145, a protein with associated tyrosine kinase activity in a human gastric carcinoma cell line. Mol Cell Biol 1988;8:3510-7. 31. Tempest PR, Cooper CS, Major GN. The activated human met gene encodes a protein tyrosine kinase. FEBS Lett 1986;209:357-61. 32. Hammond DE, Urbe S, Vande Woude GF, Clague MJ. Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 2001;20:2761-70. 33. Foveau B, Ancot F, Leroy C, Petrelli A, Reiss K, Vingtdeux V, et al. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell 2009;20:2495-507. 34. Ancot F, Leroy C, Muharram G, Lefebvre J, Vicogne J, Lemiere A, et al. Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway. Traffic 2012;13:1261-72. 35. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 2003;38:9-12. 36. Landman N, Kim TW. Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling. Cytokine Growth Factor Rev 2004;15:337-51. 37. Chalupsky K, Kanchev I, Zbodakova O, Buryova H, Jirouskova M, Korinek V, et al. ADAM10/17-dependent release of soluble c-Met correlates with hepatocellular damage. Folia Biol (Praha) 2013;59:76-86. 38. Gangemi R, Amaro A, Gino A, Barisione G, Fabbi M, Pfeffer U, et al. ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion. Pigment Cell Melanoma Res 2014;27:1138-48. 7
RkJQdWJsaXNoZXIy MTk4NDMw